• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA clears Acutus’ AcQCross system for use with Boston Scientific’s Watchman

FDA clears Acutus’ AcQCross system for use with Boston Scientific’s Watchman

June 27, 2022 By Sean Whooley

Acutus MedicalAcutus Medical (Nasdaq:AFIB) announced today that it launched an expanded suite of left-heart access products.

Following expanded FDA clearance, Acutus launched the suite to now include the AcQCross Qx system for use with the TruSeal and FXD delivery system for the Boston Scientific Watchman left atrial appendage closure device.

Carlsbad, California-based Acutus designed the AcQCross system as the first and only transseptal system engineered with an integrated needle and dilator to reduce the exchanges of wires and needles while trying to achieve the proper angle and location on the septum.

The company said in a news release that the latest FDA clearance means it now offers sheath-compatible transseptal access devices that cover 409,000 electrophysiology and structural heart procedures in the U.S.

AcQCross features a range of catheters that are length-, diameter- and tip-matched and designed to lock into the hub of market-leading sheaths used in the majority of left-heart procedures, including the delivery of the Watchman device. Acutus said the expanded offering allows physicians to use AcQCross with their preferred sheaths during virtually any left-heart access procedure.

Dr. Tom Waggoner — director of the structural heart program and cardiovascular research at the Tuscson (Arizona) Medical Center — said in the release that AcQCross gives him the means to reposition easily without withdrawing or exchanging needles or wires, while the new compatibility with Watchman makes procedures “much safer for my patients and far more efficient for me and my team.”

“The AcQCross system provides interventional cardiologists and electrophysiologists with unique benefits of broad compatibility with market-leading access sheaths while also enhancing procedure versatility and workflow,” Acutus interim CEO and CFO David Roman said in the release. “The expanded AcQCross product line allows us to bring this innovative technology to a wider range of procedure categories that should drive sustained growth in this portfolio.”

Acutus’ regulatory win comes on the heels of the sale of its left-heart access portfolio to Medtronic for $50 million in April. The company’s shares, albeit at a low price, are skyrocketing this morning, rising 82% to 98¢ per share.

“AFIB shares are trading significantly higher in pre-market trading; we view this as an incremental, expected win for the company,” BTIG analyst Marie Thibault wrote in a report.

Filed Under: Business/Financial News, Cardiovascular, Catheters, Featured, Food & Drug Administration (FDA), News Well, Regulatory/Compliance, Structural Heart, Wall Street Beat Tagged With: Acutus Medical, Boston Scientific

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy